Solid Tumors

Solid Tumors

Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection

This study investigates long-term outcomes after liver resection for HCC among patients with HBV/HCV co-infection compared with patients with HBV infection.

Frontiers in Oncology
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer

A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial...

The ASCO Post
Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma

In a pan-cancer tissue analysis that included HCC, study investigators assessed the expression of ALYREF compared to normal tissues using The Cancer Genome Atlas database.

Frontiers in Oncology

Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer

More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. 

The ASCO Post
Good Survival, Outcomes With TARE for HCC

Patients with HCC can be offered transarterial radioembolization as a safe and effective first-line treatment or adjunct to other locoregional therapies, authors of a large multicenter study report

5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine

Five-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer...

The ASCO Post
Cabozantinib in Previously Treated, Radioiodine-Refractory Differentiated Thyroid Cancer

The phase III COSMIC-311 trial has shown that cabozantinib produces a numerically higher objective response rate and significantly prolonged PFS vs placebo in patients with previously treated...

The ASCO Post
NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates

This decline is particularly prounounced for NSCLC and melanoma, according to the latest statistics in the "Annual Report to the Nation on the Status of Cancer."

Immunotherapy + Standard Chemo in Nasopharyngeal Carcinoma

The addition of the immunotherapy agent toripalimab to standard first-line CT significantly delays disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma.

Oncology Times - Latest Articles
Donafenib May Improve Survival vs Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Qin et al found that donafenib, a multikinase inhibitor and deuterated sorafenib derivative, improved OS vs sorafenib in the first-line treatment of unresectable or metastatic HCC.

The ASCO Post
HER2-Targeted Therapies Demonstrate Activity in a Range of Solid Tumor Types

The HER2-targeted drugs pertuzumab and trastuzumab were active in a variety of solid tumors with HER2 amplification/overexpression, but outcomes differed by KRAS status, according to results...

Cancer Therapy Advisor
Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma

Study investigators examine the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells, in patients with newly diagnosed high-grade glioma.

The Lancet Oncology
CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death

The current results of this study suggest that CASK expression is positively associated with sorafenib resistance and poor prognosis of HCC. 

Frontiers in Oncology
Inclusion of Patients With Brain Metastases in Phase III Trials in Advanced Breast Cancer, Lung Cancer, and Melanoma

Corbett et al find the majority of phase III trials investigating systemic therapy in patients with advanced lung cancer, breast cancer, and melanoma over the past 20 years have excluded or...

The ASCO Post
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Study investigators evaluate patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial...

The Lancet Oncology
Dual BRAF/MEK Inhibition Under Study in BRAF V600E–Mutant Gliomas

The combination of dabrafenib plus trametinib leads to encouraging and durable responses in patients with low- and high-grade gliomas harboring BRAF V600E mutations, according to the results...

The ASCO Post
Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma

This study aims to investigate safety and clinical outcome of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and targeted angiogenesis therapy in HCC of BCLC stage C.<

Frontiers in Oncology
Assessing the Safety of a Novel OX40 Agonist in Advanced Solid Tumors

Recently published data shows that BMS-986178, an investigational OX40 agonist, appears to be safe to use as monotherapy or in combination with immune checkpoint inhibitors in the treatment...

Oncology Times - Latest Articles
Updated Outcomes for Patients With Metastatic Nonseminomatous Germ Cell Tumors and Development of New Prognostic Model

Dr Silke Gillessen and colleagues in the IGCCCG Update Consortium analyze outcomes in a more contemporary cohort of men with metastatic nonseminomatous germ cell tumors.

The ASCO Post
Morning (vs Evening) Dosing and Better Survival in Glioblastoma

Timing could make a difference: new results suggest that patients with glioblastoma who took temozolomide in the morning rather than the evening showed an improved overall survival.

Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

The study demonstrates a significant improvement in overall survival with an estimated median OS of 10.9 months in the nivolumab arm compared with 8.4 months in the chemotherapy arm.

Differential Impact of ALK Mutations in Neuroblastoma

The tyrosine kinase receptor ALK can be abnormally activated in neuroblastoma, and somatic ALK mutations occur in 6%-10% of patients.

Safety and Activity of Vandetanib in Combination With Everolimus in Patients With Advanced Solid Tumors

Study investigators determine the safety, maximum tolerated dose, recommended phase II dose, and dose-limiting toxicities of VAN + EV in patients with advanced solid cancers and the effect of...

Molecular Genetics of Follicular-Derived Thyroid Cancer

This review summarizes the current literature on the molecular landscape of follicular-derived thyroid tumors.

Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing

The present review article helps clarify two intriguing points: why hypoxia-adapted cancer cells turn out radioresistant and how they can be rendered more radiosensitive.

Ablative Radiation Extends Life in Unresectable Pancreatic Cancer

For patients with inoperable pancreatic cancer, higher dose ablative radiation after chemotherapy induction may extend life.

PD-1 Immunobiology in Glomerulonephritis and Renal Cell Carcinoma

The expression and function of PD-1 molecules on immune and kidney parenchymal cells are reviewed in the healthy kidney, PD-1 immunotherapy-induced nephrotoxicity, glomerulopathies and RCC.

BMC Nephrology
Atezolizumab’s Indication in Previously Treated Metastatic Bladder Cancer Is Withdrawn

Genentech announced on March 8 the company is voluntarily withdrawing the U.S. indication for atezolizumab in patients with prior platinum-treated metastatic urothelial carcinoma.

The ASCO Post
Diffusion Histology Imaging Differentiates Distinct Pediatric Brain Tumor Histology

While conventional MRI has been widely adopted for examining pediatric high-grade brain tumors clinically, accurate neuroimaging detection and differentiation of tumor histopathology...

Scientific Reports
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers

In this article, a comprehensive review is conducted to examine potential molecular targets for BTC targeted therapy and their mechanisms.

OncoTargets and Therapy
MRI-Based Radiomics Approach for Differentiation of Hypovascular Non-Functional Pancreatic Neuroendocrine Tumors and Solid Pseudopapillary Neoplasms of the Pancreas

This study aims to investigate the value of radiomics parameters derived from contrast enhanced MRI in differentiation of hypo-NF-pNETs and solid pseudopapillary neoplasms of the pancreas.

BMC Medical Imaging
Ureteral Urothelial Carcinoma With Squamous Cell Carcinoma and Sarcomatoid Carcinoma Differentiation

Herein is a case of ureteral urothelial carcinoma with squamous cell carcinoma and sarcomatoid carcinoma differentiation and rapid ileal metastasis.

BMC Surgery
Centromere Protein U Enhances the Progression of Bladder Cancer by Promoting Mitochondrial Ribosomal Protein s28 Expression

This study investigates further the expression of two candidate genes, centromere protein U and mitochondrial ribosomal protein s28 to better understand their role in bladder cancer pathogenesis.

Korean Journal of Physiology Pharmacology

source list reference